Home / News / India News / Article /
Maharashtra FDA cancels Cipla facility's drug sale licences in Pune over violations, seizes Rs 11.11 lakh stock
Updated On: 28 August, 2026 08:33 PM IST | Pune | Archana Dahiwal
The action follows inspections conducted by the state drug regulator, which found several irregularities involving the handling, storage, records and recall of medicines

The FDA said the company did not fully comply with the required directions and procedures relating to the recall. Representational Pic/File
The Maharashtra Food and Drug Administration (FDA) has cancelled the drug sale licences of Cipla Pharma & Life Sciences Ltd.'s facility at Wadki in Pune district, citing serious violations in the storage and distribution of medicines, officials said on Friday.
The action follows inspections conducted by the state drug regulator, which found several irregularities involving the handling, storage, records and recall of medicines.


